MSB

PaySaxas Launching, Offers Global Payments, Provides Unique Solutions to Import Export Market

Retrieved on: 
Friday, April 5, 2024
JPY, Chemical oxygen demand, AML, KYC, GBP, MSB, OTC, Safety, USDT, Cryptocurrency

VANCOUVER, CANADA, April 05, 2024 (GLOBE NEWSWIRE) -- PaySaxas, the newest entrant of the cross border transaction industry, has announced it has launched global payments, providing exclusive and unique solutions for international trade, including in-house crypto OTC.

Key Points: 
  • VANCOUVER, CANADA, April 05, 2024 (GLOBE NEWSWIRE) -- PaySaxas, the newest entrant of the cross border transaction industry, has announced it has launched global payments, providing exclusive and unique solutions for international trade, including in-house crypto OTC.
  • The PaySaxas Smart Payments Platform focuses on specific features, that have long been in demand by the global trade industry.
  • The emerging trend provides customers immediate and direct access to the decision makers rather than lengthy delays.
  • With multilingual support and a team that understands the pains of global trade, the PaySaxas solution offers customers more payment solutions, and less hassle with daily transactions, leaving them to focus on their revenue and business growth.

Madrascoin (MAA) Listed on the Leading Global Cryptocurrency Exchange Crisuper Pro

Retrieved on: 
Thursday, April 4, 2024
Professional, MSB, Growth, Money services business, MAA, Cryptocurrency

New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Madrascoin (MAA), a cryptocurrency that has garnered widespread market attention, recently announced its listing on the leading global cryptocurrency exchange, Crisuper Pro.

Key Points: 
  • New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Madrascoin (MAA), a cryptocurrency that has garnered widespread market attention, recently announced its listing on the leading global cryptocurrency exchange, Crisuper Pro.
  • The successful listing of Madrascoin not only showcases its potential in the cryptocurrency field but also demonstrates the strong appeal of Crisuper Pro as a compliance-focused exchange.
  • As one of the leading global cryptocurrency exchanges, Crisuper Pro not only supports a variety of innovative cryptocurrency projects but also provides a stable and reliable trading platform for global users.
  • The successful collaboration between Madrascoin and Crisuper Pro not only fuels market prosperity but also sets a new benchmark for global cryptocurrency exchanges.

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Retrieved on: 
Tuesday, March 26, 2024
Patient, MESO, Mesoblast, U.S. FDA, MSB, FDA, BLA, Inflammation

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).
  • “We thank the agency for their collaborative approach.
  • The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD,” said Mesoblast CEO Dr. Silviu Itescu.
  • Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.

Unlocking Financial Freedom: Meet Keytom, The All-in-One Neobank for Digital Assets

Retrieved on: 
Tuesday, April 9, 2024
USDT, VASP, MSB, Neobank, Growth, Heart, Environment, Safety, Cryptocurrency

Keytom harnesses a diverse array of financial services, catering to the needs of individuals and businesses across the realms of both traditional fiat and cryptocurrencies.

Key Points: 
  • Keytom harnesses a diverse array of financial services, catering to the needs of individuals and businesses across the realms of both traditional fiat and cryptocurrencies.
  • At its core, the company champions financial empowerment, positioning itself as the 'one bank for all digital assets'.
  • Keytom's vision lies in dismantling financial barriers and uniting fiat and crypto domains within a cohesive framework accessible to everyone.
  • The neobank's clients can oversee their funds via a unified interface accessible through web browsers or a mobile application.

VirtualDime Launches on FutureBitX Exchange, Leading the Financial Technology

Retrieved on: 
Friday, March 15, 2024
VDD, MSB, Decentralized finance, CO, Cryptocurrency

FutureBitX Exchange, located at the forefront of this revolution, recently witnessed the official launch of VirtualDime (VDD), a decentralized finance (DeFi) project built on Web3 technology.

Key Points: 
  • FutureBitX Exchange, located at the forefront of this revolution, recently witnessed the official launch of VirtualDime (VDD), a decentralized finance (DeFi) project built on Web3 technology.
  • VirtualDime, a decentralized finance (DeFi) project built on Web3 technology, has garnered attention for its innovative financial solutions and solid technical foundation.
  • The launch of VirtualDime on FutureBitX is not only a significant achievement of collaboration between the two companies but also a significant step forward for the entire financial technology sector.
  • With their collaboration, the market has reason to expect that FutureBitX and VirtualDime will jointly usher in a new wave in the global financial technology sector, bringing unprecedented financial service experiences for users.

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Retrieved on: 
Wednesday, March 13, 2024
Principal, LVAD, MESO, Patient, Heart failure, MSB, FDA, Entitlement, Inflammation

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer).

Key Points: 
  • NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer).
  • Together the entitlement offer and institutional placement raised gross proceeds of A$97 million, including A$36.7 million committed today on the same terms as the Entitlement Offer, primarily from Mesoblast’s existing major shareholders.
  • Dr. Eric Rose, the Company’s Chief Medical Officer and a director of Mesoblast, subscribed for additional shares of A$1.5 million, subject to shareholder approval.
  • Dr. Rose is a world-renowned heart surgeon who performed the world’s first successful heart transplant in children and was for many years Chairman of Columbia University’s Department of Surgery.

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Retrieved on: 
Sunday, March 10, 2024
Heart, Licensure, MPC, Incidence, Regenerative Medicine Advanced Therapy, MSB, Inflammation, IL-6, FDA, U.S. FDA, BLA, MESO, Patient, Type, LVAD, Mortality, Pharmaceutical industry

“We are very pleased with FDA’s feedback that the presented results from our pivotal study of rexlemestrocel-L in end-stage HFrEF patients with LVADs may support an accelerated approval,” said Mesoblast CEO Dr. Silviu Itescu.

Key Points: 
  • “We are very pleased with FDA’s feedback that the presented results from our pivotal study of rexlemestrocel-L in end-stage HFrEF patients with LVADs may support an accelerated approval,” said Mesoblast CEO Dr. Silviu Itescu.
  • “We intend to request a pre-Biologics License Application (BLA) meeting to discuss data presentation, timing and FDA expectations for an accelerated approval filing.”
    Every year in the United States over 100,000 patients progress to end-stage HFrEF.
  • In contrast, in ischemic patients treated with rexlemestrocel-L, IL-6 levels returned to normal by 2 months and remained low through 12 months.
  • Mesoblast intends to request a pre-BLA meeting with FDA to discuss data presentation, timing and FDA expectations for an accelerated approval filing in end-stage ischemic HFrEF patients with LVAD implantation.

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Retrieved on: 
Wednesday, February 28, 2024
DREAM, RPD, Growth, PLI, SIX, BMT, FIRST, Diagnosis, Mortality, Bangladesh Technical Education Board, Blood, HLHS, MSB, Degenerative disc disease, NIH, Marketing, Pain, MACE, BLA, Survival, Heart failure, Hypoplastic left heart syndrome, LVAD, Randomized controlled trial, FINANCIAL, Inflammation, Biopharmaceutical, ODD, Heart, Mesoblast, Regenerative Medicine Advanced Therapy, FDA, Priority review, MESO, Risk, Administration, Death, Patient, PRV, DDD, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023.
  • Reduction in net cash usage for operating activities:
    For the three months ended December 31, 2023, net cash usage was US$12.3 million, a 25% reduction versus the comparative quarter in FY2023.
  • For the six months ended December 31, 2023, net cash usage was US$26.6 million, a 14% reduction versus the comparative period in FY2023.
  • Manufacturing reduced by 47% for the six months ended December 31, 2023, from US$12.8 million to US$6.7 million.

New Journey in Compliance: BAORUI Proudly Acquires the US MSB License, Marking a Financial Milestone

Retrieved on: 
Monday, February 26, 2024
Acquisition, MSB, Cryptocurrency

Furthermore, it symbolizes its dazzling achievement in the crypto market, boasting both US and Canadian MSB licenses.

Key Points: 
  • Furthermore, it symbolizes its dazzling achievement in the crypto market, boasting both US and Canadian MSB licenses.
  • Andrew Griffiths, the head of the BAORUI brand, proclaimed, “Successfully obtaining the US MSB license is a robust affirmation of BAORUI’s long-standing adherence to compliance and its dedication to delivering high-quality financial services.
  • However, backed by its consistent emphasis on regulatory compliance and profound operational strength, BAORUI stood out and earned this prestigious license.
  • It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

Mesoblast Financial Results and Corporate Update Webcast

Retrieved on: 
Monday, February 26, 2024
EST, MSB, Webcast, Inflammation, AEDT, MESO

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the six months ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the six months ended December 31, 2023.
  • The webcast will begin at 5.00pm EST, Wednesday, February 28; 9.00am AEDT, Thursday, February 29, 2024.
  • It can be accessed via: https://webcast.openbriefing.com/msb-hyr-2024/
    The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com